Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Abdul Basit

Showing results (731-740 of 746) with videos related to

Pageof 75
Sort By:
Acta Tropica|March 7, 2020
Sentinel surveillance of selected veterinary and public health pathogens in camel population originating from Southern Punjab province, PakistanMuhammad Zubair Shabbir, Tayyebah Sohail, Aziz Ul-Rahman, et al.
Journal of Human Hypertension|April 29, 2026
Consensus on the management of hypertension in individuals with diabetes by Asian-Pacific Society of hypertension (APSH) & Diabetes Asia Study Group (DASG)Anuj Maheshwari, Banshi Saboo, Boon Wee Teo, et al.
Nature Metabolism|February 26, 2021
Consequences of the COVID-19 pandemic for patients with metabolic diseasesStefan R Bornstein, Francesco Rubino, Barbara Ludwig, et al.
Bioorganic & Medicinal Chemistry Letters|July 20, 2017
Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritisSobhana Babu Boga, Abdul-Basit Alhassan, Jian Liu, et al.
Bioorganic & Medicinal Chemistry Letters|March 4, 2017
Discovery of novel BTK inhibitors with carboxylic acidsXiaolei Gao, James Wang, Jian Liu, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid ArthritisJian Liu, Deodial Guiadeen, Arto Krikorian, et al.
Bioorganic & Medicinal Chemistry Letters|May 12, 2018
Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncologySobhana Babu Boga, Abdul-Basit Alhassan, Alan B Cooper, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2020
Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutesJian Liu, Deodial Guiadeen, Arto Krikorian, et al.
The Lancet. Diabetes & Endocrinology|October 7, 2021
COVID-19 and metabolic disease: mechanisms and clinical managementCharlotte Steenblock, Peter E H Schwarz, Barbara Ludwig, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for OncologySobhana Babu Boga, Yongqi Deng, Liang Zhu, et al.
Pageof 75

Showing results (731-740 of 746) with videos related to

Sort By:
Pageof 75
Acta Tropica|March 7, 2020
Sentinel surveillance of selected veterinary and public health pathogens in camel population originating from Southern Punjab province, PakistanMuhammad Zubair Shabbir, Tayyebah Sohail, Aziz Ul-Rahman, et al.
Journal of Human Hypertension|April 29, 2026
Consensus on the management of hypertension in individuals with diabetes by Asian-Pacific Society of hypertension (APSH) & Diabetes Asia Study Group (DASG)Anuj Maheshwari, Banshi Saboo, Boon Wee Teo, et al.
Nature Metabolism|February 26, 2021
Consequences of the COVID-19 pandemic for patients with metabolic diseasesStefan R Bornstein, Francesco Rubino, Barbara Ludwig, et al.
Bioorganic & Medicinal Chemistry Letters|July 20, 2017
Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritisSobhana Babu Boga, Abdul-Basit Alhassan, Jian Liu, et al.
Bioorganic & Medicinal Chemistry Letters|March 4, 2017
Discovery of novel BTK inhibitors with carboxylic acidsXiaolei Gao, James Wang, Jian Liu, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid ArthritisJian Liu, Deodial Guiadeen, Arto Krikorian, et al.
Bioorganic & Medicinal Chemistry Letters|May 12, 2018
Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncologySobhana Babu Boga, Abdul-Basit Alhassan, Alan B Cooper, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2020
Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutesJian Liu, Deodial Guiadeen, Arto Krikorian, et al.
The Lancet. Diabetes & Endocrinology|October 7, 2021
COVID-19 and metabolic disease: mechanisms and clinical managementCharlotte Steenblock, Peter E H Schwarz, Barbara Ludwig, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for OncologySobhana Babu Boga, Yongqi Deng, Liang Zhu, et al.
Pageof 75